Statistical Genomic Approach Identifies Association between FSHR Polymorphisms and Polycystic Ovary Morphology in Women with Polycystic Ovary Syndrome

Table 1

Demographic characteristics and endocrine profiles of PCOS women with or without polycystic ovary morphology.

	Non-PCO	PCO	value
Case number	63	384	—
Age, year	26.86 ± 3.65	27.18 ± 3.92	0.55
BMI, kg/m^2	23.28 ± 9.47	22.83 ± 4.70	0.74
WHR	0.84 ± 0.21	0.82 ± 0.07	0.67
Acne score	1 (0–4)	0 (0–5)	0.049
mF-G score	6 (0–22)	4 (0–35)	0.35
CHOL, mmol/L	4.73 ± 0.75	4.97 ± 0.87	0.08
TG, mmol/L	1.26 ± 0.73	1.32 ± 0.84	0.67
HDL-C, mmol/L	1.62 ± 0.48	1.57 ± 0.44	0.51
LDL-C, mmol/L	2.62 ± 0.67	2.92 ± 0.82	0.02
HOMA-IR	2.19 ± 1.72	2.34 ± 1.98	0.59
HOMA-ISI	0.03 ± 0.02	0.03 ± 0.03	0.71
HOMA-β%	135.96 ± 115.58	131.87 ± 130.32	0.82
FSH, IU/L	6.68 ± 2.34	6.46 ± 2.33	0.51
LH, IU/L	10.24 ± 7.80	10.88 ± 6.99	0.53
PRL, ng/mL	16.00 ± 10.47	16.63 ± 11.20	0.70
E2, ng/L	84.62 ± 93.91	71.45 ± 75.47	0.34
TT, nmol/L	2.41 ± 1.02	2.40 ± 1.31	0.99
A2, ng/mL	4.80 ± 2.22	5.22 ± 2.46	0.37
FT, pg/mL	3.65 ± 3.01	4.67 ± 5.68	0.04
DHEA-S, ng/mL	2245.25 ± 1009.03	2159.46 ± 1007.76	0.54
E1, pg/mL	101.77 ± 37.95	117.18 ± 83.34	0.23
SHBG, nmol/L	85.10 ± 72.80	64.20 ± 55.802	0.04
17-OHP, ng/mL	1.17 ± 1.00	1.27 ± 0.87	0.43

Significant difference was in bold.
PCO: polycystic ovary; BMI: body mass index; WHR: waist-hip ratio; mF-G score: modified Ferriman-Gallwey score; CHOL: cholesterol; TG: triglycerides; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol; HOMA-IR/HOMA-ISI/HOMA-β%: homeostatic model assessment for insulin resistance/insulin sensitivity/β; FSH: follicle stimulating hormone; LH: luteinizing hormone; PRL: prolactin; E2: estradiol; TT: total testosterone; A2: androstenedione; FT: free testosterone; DHEA-S: dehydroepiandrosterone sulfate; E1: estrone; SHBG: sex hormone binding globulin; 17-OHP: 17-hydroxyprogesterone.